Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: Insights from a patient-level pooled analysis of six randomized clinical trials☆
Keywords
Cited by (0)
Conflicts of interest: V.F. has received advisory board honoraria and speakers’ bureau honoraria from Novo Nordisk, and his institution has received research funding from Novo Nordisk; V.F. is currently Editor-in-Chief of this journal. J.H.D. or his institution has received advisory board honoraria and speakers’ bureau honoraria from Novo Nordisk, and his institution has received research funding from Novo Nordisk. R.H.’s institution has received research funding from Novo Nordisk. J.P. has received consultancy fees from Novo Nordisk. M.D. and H.T. are currently employed by and own shares in Novo Nordisk A/S. These analyses were sponsored by Novo Nordisk A/S, Copenhagen, Denmark. All authors discussed the data, edited the manuscript for important intellectual content, and approved the version for publication. H.T carried out the statistical analyses.
- ☆
Clinical trial registration: This patient-level pooled analysis is based on data from the following six clinical trials, registered at ClinicalTrials.gov: NCT00318422, NCT00318461, NCT00294723, NCT00333151, NCT00331851, NCT00518882.